Show simple item record

dc.contributor.authorBoudghene-Stambouli, Fadia
dc.contributor.authorSoulez, Mathilde
dc.contributor.authorRonkina, Natalia
dc.contributor.authorDörrie, Anneke
dc.contributor.authorKotlyarov, Alexey
dc.contributor.authorSeternes, Ole Morten
dc.contributor.authorGaestel, Matthias
dc.contributor.authorMeloche, Sylvain
dc.date.accessioned2023-08-23T07:55:43Z
dc.date.available2023-08-23T07:55:43Z
dc.date.issued2022-12-21
dc.description.abstractERK3 and ERK4 define a distinct and understudied subfamily of mitogen-activated protein kinases (MAPKs). Little is known about the physiological roles of these atypical MAPKs and their association with human diseases. Interestingly, accumulating evidence points towards a role for ERK3 and ERK4 signaling in the initiation and progression of various types of cancer. Notably, a recent study reported that ERK4 is expressed in a subset of triple-negative breast cancer (TNBC) cell lines and that this expression is critical for AKT activation and for sustaining TNBC cell proliferation in vitro and tumor growth in mice. The authors also showed that depletion of ERK4 sensitizes TNBC cells to phosphatidylinositol-3-kinase (PI3K) inhibitors. They concluded that ERK4 is a promising therapeutic target for TNBC and has potential for combination therapy with PI3K inhibitors. Here, we raise concerns about the cellular models and experimental approaches used in this study, which compromise the conclusions on the oncogenic role of ERK4 in TNBC.en_US
dc.identifier.citationBoudghene-Stambouli, Soulez M, Ronkina, Dörrie, Kotlyarov, Seternes om, Gaestel M, Meloche S. On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer. Cancers. 2023;15(1)en_US
dc.identifier.cristinIDFRIDAID 2114716
dc.identifier.doi10.3390/cancers15010025
dc.identifier.issn2072-6694
dc.identifier.urihttps://hdl.handle.net/10037/30202
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.journalCancers
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleOn the Therapeutic Potential of ERK4 in Triple-Negative Breast Canceren_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)